Bibliography
- Winblad B , KilanderL, ErikssonSet al.: For the Severe Alzheimer‘s Disease Study Group: Donepezil in patients with severe Alzheimer‘s disease: double blind, parallel group, placebo controlled study.Lancet367, 1057–1065 (2006)
- Cummings JL : Treatment of Alzheimer‘s disease: current and future therapeutic approaches.Rev. Neuro. Disorders1, 60–69 (2004).
- Loveman E , GreenC, KirbyJet al.: Clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer‘s disease.Health Tech. Assess.10, 1–160 (2006).
- Feldman H , Gauthier S, Hecker Jet al.: Efficacy and safety of donepezil in patients with more severe Alzheimer‘s disease: a subgroup analysis from a randomised placebo-controlled trial. Int. J. Geriatric Soc.20, 559–569 (2005).
- Tariot P , CummingsJL, KatzIRet al.: A randomised, double blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer‘s disease in the nursing home setting.J. Geriatric Soc.49, 1590–1599 (2001).
- Lopez OL , BeckerT, Wisniewiskiet al.: Cholinesterase inhibitor treatment alters the natural history of Alzheimer‘s disease. J. Neurol. Neurosurg. Psych.72, 310–314 (2002).
- Steinman MA , CovinskyKE: Donepezil for nursing home patients with dementia: a reinterpretation of the evidence.J. Am. Geriatric Soc.51, 132–133 (2003).
- Winblad B , EngedalG, SoininenHet al.: A 1 year randomised placebo controlled study of donepezil in patients with mild to moderate Alzheimer‘s disease.Neurology57, 489–495 (2001).
- Akaike A : Preclinical evidence of neuroprotection by cholinesterase inhibitors.Alz. Dis. Assoc. Disord.2(Suppl. 1), S8–S11 (2006).
- Mosi E , HashimotoM, KrishnanKR, DoraswaimyPM: What constitutes clinical evidence for neuroprotection in Alzheimer‘s disease: support for cholinesterase inhibitors.Alz. Dis. Assoc. Disord.2(Suppl. 1), S19–S26 (2006).
- Ranga-Rawa-Krishan L , Cecil-CharlesHC, DoraiswamyPMet al.: Randomized placebo controlled trial of the effects of donepezil on neuronal markers and hippocampal volumes in Alzheimer‘s disease.Am. J. Psychiatry160, 2003–2011 (2003).
- Hushimoto M , KazuiH, MatsumotoKet al.: Does donepezil treatment slow the progression of hippocampal atrophy in patients with Alzheimer‘s Disease?Am. J. Psychiatry162, 676–682 (2005).
- Kihara T , ShimoharaS, SawadaHet al.: Nicotinic receptor stimulation protects neurones against β-amyloid toxicity.Ann. Neurol.42, 159–163 (1997).
- Svensson AL , NordbergA: Tacrine and donepezil attenuate the neurotoxic effects of A-β (23–25) in rat PC12 cells.Neuroreport9, 15–19 (1998).
Websites
- National Institute for Clinical Excellence (NICE). Alzheimers disease – donezepil, rivastigmine and galantamine. Technology Appraisal No 19. www.nice.org.uk
- National Institute for Healthcare and Clinical Excellence (NICE). Final appraisal document for review of Technology appraisal No 19. Donepezil, galantamine, rivastigmine (review) and memantine for the treatment of Alzheimers disease. www.nice.org.uk